Jubilant Ingrevia Buys 40% Stake in Zettaone for Rs 189.2 Cr

Jubilant Ingrevia has finalized a binding agreement to secure a 40% strategic stake in Zettaone Technologies India. This significant acquisition is valued at Rs 189.2 crore, integrating the technology firm into Jubilant Ingrevia’s broader operational framework.

Transaction Details and Timeline

The proposed acquisition will establish Zettaone Technologies as an associate company under Jubilant Ingrevia’s umbrella. This complex transaction is structured to be completed through a phased approach over the next few years, ensuring a smooth integration process.

• The first tranche of the acquisition is projected to close by November 2026.
• The second and final tranche is expected to conclude by September 2027.

Strategic Market Expansion

This move is designed to allow Jubilant Ingrevia to capitalize further on its established manufacturing prowess and customer-centric approach within the Contract Development and Manufacturing Organization (CDMO) sector. The company anticipates strengthening its strategic engagements with key customers across the burgeoning electronics and semiconductor value chain, indicating a clear intent for diversified growth.

Jubilant Ingrevia operates as a global integrated provider, delivering Life Science products and innovative solutions across multiple industries. Its extensive client portfolio includes leading players in the Pharmaceutical, Nutrition, Agrochemical, Consumer, and Industrial segments, highlighting its broad market presence.